Published in Pediatr Res on April 06, 2005
The two stage model of preeclampsia: variations on the theme. Placenta (2008) 2.78
Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond) (2009) 2.31
Maternal uterine vascular remodeling during pregnancy. Physiology (Bethesda) (2009) 1.85
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol (2008) 1.82
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol (2009) 1.50
Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension (2009) 1.49
Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension (2009) 1.46
Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens (2009) 1.41
Vitamin D may be a link to black-white disparities in adverse birth outcomes. Obstet Gynecol Surv (2010) 1.40
Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am J Hypertens (2008) 1.22
Vascular endothelial growth factor in heart failure. Nat Rev Cardiol (2013) 1.16
First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 1.08
Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07
Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol (2010) 1.05
Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol (2013) 1.03
Exercise training attenuates placental ischemia-induced hypertension and angiogenic imbalance in the rat. Hypertension (2012) 0.96
Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev Cardiovasc Ther (2008) 0.94
Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice. Am J Hypertens (2010) 0.94
L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. Am J Physiol Regul Integr Comp Physiol (2011) 0.93
Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol (2008) 0.92
Placental growth hormone is increased in the maternal and fetal serum of patients with preeclampsia. J Matern Fetal Neonatal Med (2007) 0.91
Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat. Am J Physiol Regul Integr Comp Physiol (2012) 0.90
The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy. FASEB J (2011) 0.90
Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med (2010) 0.88
Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol (2010) 0.88
Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium. Cardiovasc Res (2010) 0.88
Regulation of trophoblast invasion: the role of matrix metalloproteinases. Rev Obstet Gynecol (2012) 0.87
Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med (2007) 0.86
Preeclampsia and the risk of bronchopulmonary dysplasia in VLBW infants: a population based study. PLoS One (2013) 0.86
Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol (2008) 0.86
Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med (2008) 0.86
The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front Pharmacol (2014) 0.85
Biomarkers for the management of pre-eclampsia in pregnant women. Indian J Med Res (2013) 0.84
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med (2008) 0.84
Hypoxia-inducible factor 1alpha (HIF1A) mediates distinct steps of rat trophoblast differentiation in gradient oxygen. Biol Reprod (2008) 0.83
Maternal circulating angiogenic factors in twin and singleton pregnancies. Am J Obstet Gynecol (2014) 0.83
Inhibition of nitric oxide synthases abrogates pregnancy-induced uterine vascular expansive remodeling. J Vasc Res (2009) 0.82
AICAR administration ameliorates hypertension and angiogenic imbalance in a model of preeclampsia in the rat. Am J Physiol Heart Circ Physiol (2013) 0.81
Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia. Hypertension (2013) 0.80
Vasopressin: the missing link for preeclampsia? Am J Physiol Regul Integr Comp Physiol (2015) 0.80
In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One (2014) 0.80
Heme oxygenase-1 is critically involved in placentation, spiral artery remodeling, and blood pressure regulation during murine pregnancy. Front Pharmacol (2015) 0.79
Preeclampsia and Retinopathy of Prematurity in Very-Low-Birth-Weight Infants: A Population-Based Study. PLoS One (2015) 0.79
Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One (2015) 0.78
Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med (2015) 0.78
Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia. Cardiovasc J Afr (2013) 0.77
Preeclampsia, gestational hypertension and subsequent hypothyroidism. Pregnancy Hypertens (2012) 0.77
Variability in mRNA expression of fms-like tyrosine kinase-1 variants in normal and preeclamptic placenta. BMC Res Notes (2014) 0.76
Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Am J Obstet Gynecol (2016) 0.76
The effects of S-nitrosoglutathione and S-nitroso-N-acetyl-D, L-penicillamine in a rat model of pre-eclampsia. J Nat Sci Biol Med (2013) 0.76
High levels of HtrA4 observed in preeclamptic circulation drastically alter endothelial gene expression and induce inflammation in human umbilical vein endothelial cells. Placenta (2016) 0.75
Low Soluble Syndecan-1 Precedes Preeclampsia. PLoS One (2016) 0.75
Multiple soluble TGF-β receptors in addition to soluble endoglin are elevated in preeclamptic serum and they synergistically inhibit TGF-β signalling. J Clin Endocrinol Metab (2017) 0.75
The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One (2017) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics (2010) 3.39
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol (2005) 2.04
Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol (2004) 2.03
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol (2009) 1.95
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation (2009) 1.85
Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int (2010) 1.83
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab (2002) 1.79
Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis (2012) 1.72
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Postpartum diabetes screening in women with a history of gestational diabetes. Obstet Gynecol (2005) 1.70
Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol (2011) 1.70
Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 1.69
Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract (2007) 1.67
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
Metabolite profiling identifies markers of uremia. J Am Soc Nephrol (2010) 1.63
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ (2009) 1.59
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension (2007) 1.56
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54
Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem (2002) 1.51
The glomerular injury of preeclampsia. J Am Soc Nephrol (2007) 1.50
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
Nutritional vitamin D in dialysis patients: what to D-iscern? Nephrol Dial Transplant (2011) 1.49
Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int (2013) 1.48
Familial factors in the association between preeclampsia and later ESRD. Clin J Am Soc Nephrol (2012) 1.47
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clin J Am Soc Nephrol (2010) 1.44
Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int (2004) 1.42
First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care (2003) 1.41
First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension (2010) 1.39
Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem (2005) 1.36
Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol (2011) 1.35